• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    PIIS1040842816301056.pdf
    Size:
    460.2Kb
    Format:
    PDF
    Description:
    Open access full text article
    Download
    Authors
    Zinzani, P
    Sasse, S
    Radford, John A
    Gautam, A
    Bonthapally, V
    Affiliation
    Institute of Hematology and Medical Oncology, 'L. & A. Seragnoli', University of Bologna, Bologna, Italy
    Issue Date
    2016-08
    
    Metadata
    Show full item record
    Abstract
    Brentuximab vedotin was available via named patient program (NPP) to patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma in ∼60 non-US/Canadian countries, before local approval. Published results were examined recently; through systematic literature review, we identified 12 new NPP publications. Most (10/12) publications included new NPP data describing 8 unique cohorts (N=480; all R/R HL) and new participating countries. Overall response rates were 58-80%, and complete remission rates were 10-40%. With median follow-up of 9.5-26 months, median progression-free survival was 5-10.5 months and median overall survival (OS) had not been reached in most cohorts; 1- and 2-year OS was 67-76% and 58-67%, respectively. Tolerability was as expected from previous reports. Despite intrinsic bias and heterogeneous cohorts, this update supports previous findings showing comparable efficacy and tolerability of brentuximab vedotin between real-world practice and phase 2 trial results in R/R HL.
    Citation
    Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. 2016, 104:65-70 Crit Rev Oncol Hematol
    Journal
    Critical Reviews in Oncology/Hematology
    URI
    http://hdl.handle.net/10541/618151
    DOI
    10.1016/j.critrevonc.2016.04.019
    PubMed ID
    27279289
    Type
    Article
    Language
    en
    ISSN
    1879-0461
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.critrevonc.2016.04.019
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
    • Authors: Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, Engert A, von Tresckow B, Skoetz N
    • Issue date: 2018 Jul 12
    • Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
    • Authors: Zinzani PL, Sasse S, Radford J, Shonukan O, Bonthapally V
    • Issue date: 2015 Sep
    • Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.
    • Authors: Dada R, Zekri J, Al Saadi R
    • Issue date: 2016 Jun
    • The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    • Authors: Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F
    • Issue date: 2016 Jan
    • Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
    • Authors: Martino M, Festuccia M, Fedele R, Console G, Cimminiello M, Gavarotti P, Bruno B
    • Issue date: 2016
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.